Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells.
about
HEPACAM1 and 2 are differentially regulated in canine mammary adenomas and carcinomas and its lymph node metastasesMetastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profilesThe roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox11q deletion in neuroblastoma: a review of biological and clinical implications.Functional significance of the hepaCAM gene in bladder cancerEffects of smoking cessation on gene expression in human leukocytes of chronic smokerThe SMAD2/3 pathway is involved in hepaCAM-induced apoptosis by inhibiting the nuclear translocation of SMAD2/3 in bladder cancer cells.Expression of hepaCAM inhibits bladder cancer cell proliferation via a Wnt/β-catenin-dependent pathway in vitro and in vivoIdentification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma.HepaCAM associates with connexin 43 and enhances its localization in cellular junctions.Molecular biological aspects on canine and human mammary tumors.Regulatory-auxiliary subunits of CLC chloride channel-transport proteins.HEPACAM inhibited the growth and migration of cancer cells in the progression of non-small cell lung cancer.Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer.HepaCAM inhibits clear cell renal carcinoma 786-0 cell proliferation via blocking PKCε translocation from cytoplasm to plasma membrane.HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma.Down-regulation of mechanisms involved in cell transport and maintenance of mucosal integrity in pigs infected with Lawsonia intracellularis.Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway.
P2860
Q21203572-A2CC975B-6C14-46DA-AABE-CC4D8F7DB349Q21261300-EEAD8382-380C-4F7F-A13B-616D68C3960EQ24649969-D6DA38CB-732E-46F6-85E6-241B3DA868CCQ32174267-C3082FE0-2850-401D-8CA2-7A595C6C5EDFQ33537496-5702140D-F02F-40CD-91F7-6C3EF3D1827AQ34012242-09716281-4B94-4C8A-97D5-1B2F25F32F81Q35922961-B4C96E79-23A5-41B9-8986-F18CEA828EDDQ36839010-5D8376EA-254D-4471-A4EA-4C81FD6AB79AQ37376261-E9A7B58D-76F4-4D2A-B30A-615D1366A122Q37397225-E37BBC5F-AA23-4FD5-B881-E17D2234FF4DQ37819443-A379902D-6926-4264-A787-1637C637FC79Q38374425-42784340-4937-492D-B200-442471F6DEC7Q38833700-3733578C-021C-4D88-9D6A-64DF7D71FF6AQ38996973-EA3FA204-2C2D-4AF9-8102-C44466532530Q39025188-CE804F07-05D2-4C70-9A95-BC2E8C0BF588Q39535046-2C83CA79-925D-4EDD-A714-7F9ABB093740Q39876741-19684546-3011-433D-8AFA-07E1D91922BAQ51126611-55BBEA74-F2B4-47C8-A898-E0D717061E57
P2860
Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Expression of hepaCAM is downr ...... in human breast cancer cells.
@ast
Expression of hepaCAM is downr ...... in human breast cancer cells.
@en
Expression of hepaCAM is downr ...... in human breast cancer cells.
@nl
type
label
Expression of hepaCAM is downr ...... in human breast cancer cells.
@ast
Expression of hepaCAM is downr ...... in human breast cancer cells.
@en
Expression of hepaCAM is downr ...... in human breast cancer cells.
@nl
prefLabel
Expression of hepaCAM is downr ...... in human breast cancer cells.
@ast
Expression of hepaCAM is downr ...... in human breast cancer cells.
@en
Expression of hepaCAM is downr ...... in human breast cancer cells.
@nl
P2093
P356
P1433
P1476
Expression of hepaCAM is downr ...... in human breast cancer cells.
@en
P2093
Lay Hoon Lee
Mei Chung Moh
Shali Shen
Ting Zhang
P304
P356
10.1093/CARCIN/BGN226
P407
P577
2008-10-08T00:00:00Z